相关实验视频

Updated: Sep 14, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

针对肺状细胞癌中的SLC7A5:对癌症代谢转移和中子捕获疗法耐药性的影响

Yen-Ju Lin^1,2, Yu-Cheng Wu¹, Yu-Jui Liu¹

¹Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan.

|July 23, 2025

概括

肺状细胞癌 (LUSC) 中SLC7A5输送体表达升高与预后不佳相关. 抑制SLC7A5可以通过向自途径来克服对中子捕获疗法 (BNCT) 的抗性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症治疗方法癌症治疗方法

背景情况:

状细胞癌 (SCC) 缺乏有效的治疗方法.
中子捕获疗法 (BNCT) 对各种癌症具有前景.
SLC7A5载体在BNCT和SCC耐药性的作用尚不清楚.

研究的目的:

研究SCC亚型中的SLC7A5表达.
确定SLC7A5在肺状细胞癌 (LUSC) 抵抗烯氨酸-BNCT (BPA-BNCT) 的作用.
探索针对SLC7A5和相关途径的治疗策略.

主要方法:

在SCC组织中分析了SLC7A5表达.
在LUSC细胞中使用了SLC7A5敲击和敲击.
进行了RNA测序 (RNA-seq) 分析.
评估细胞活力和细胞亡.
对BPA-BNCT和黄素的评估敏感性.

主要成果:

大多数SCC显示SLC7A5升高,特别是LUSC.
在LUSC中高SLC7A5和T/N比率预测预后不佳.
在LUSC细胞中抑制SLC7A5会减少增殖并增加亡.
SLC7A5淘汰赛LUSC细胞表现出BPA-BNCT耐药性,但对氨酸敏感.
在BNCT后存活的细胞显示SLC7A5降低和克洛洛敏感性增加.

结论:

SLC7A5是LUSC进展和BPA-BNCT耐药性的关键因素.
抑制SLC7A5会影响mTORC1信号传递,氨基酸运输和自.
用洛奎因向自可以克服LUSC中的BPA-BNCT耐药性.
研究结果提供了提高BPA-BNCT在SCC中的疗效的策略.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...